Study summary · 2026 · Implementation

Hypertension RPM costs and provider return on investment

Provider profitability was sensitive to staffing costs, reimbursement and patient participation.

Summary by Vironix Health · Source review: November 11, 2026
How we select and interpret evidence

Original publication

Program cost and return on investment analysis of remote patient monitoring for hypertension management in the cardiology department of a large healthcare system

Donglan S Zhang; Laure Millet; Brandon K Bellows; Sarah Lee; Devin Mann

NYU Grossman Long Island School of Medicine; NYU Grossman School of Medicine; NYU Langone Health; Columbia University Irving Medical Center

Journal of Telemedicine and Telecare · Online: · Issue: September 2026

2026 journal article superseding the 2025 medRxiv preprint (PMID 39974005). · Summary limited to the accessible abstract.

What was studied

Design
Implementation
Population
One cardiology division's hypertension RPM program
Sample
Single-program costing study; patient denominator not stated in abstract
Intervention
Home BP monitoring and telehealth services
Comparator
Program costs versus estimated reimbursement
Follow-up
Cost observations March–June 2024; per-patient horizon not specified in journal abstract
Setting
United States; NYU Langone Health

Methods

Observation, surveys and micro-costing using 2024 prices and estimated Medicare reimbursement.

Findings

The abstract reports a positive average provider ROI, but sensitivity estimates included losses; data review was the largest reported cost component.

Limitations

Single-center financial analysis, not a causal outcomes or payer-savings study. This summary is limited to the journal abstract; it does not use preprint-only details.

What this means for care delivery

Use local workload and payment assumptions when evaluating sustainability; historical estimates are not current billing guidance.